Novitero

Company Overview

Snapshot

Founded in February 2014 by Itzchak Angel, PhD, Novitero operates with 1–10 employees. The company has raised $50,000 across one funding round. Novitero ceased operations in January 2021.

Business overview

Novitero is a computational drug design and development company focused on creating precise and effective cancer treatments. The company's core technology involves predicting and bypassing potential mutations that cancer may adopt to resist therapies. It uses computational methods to identify mutational fingerprints implicated in drug resistance to various therapeutic targets, then designs, validates, and out-licenses new drugs to overcome these mutations. Novitero operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the biotechnology and pharmaceutical industries.

Company Intelligence Q&A

What is Novitero's primary focus?

Novitero is a computational drug design and development company focused on enabling precise and effective cancer treatments by bypassing resistance mutations.

When was Novitero founded?

Novitero was founded in February 2014.

Who founded Novitero?

Novitero was founded by Itzchak Angel, PhD.

What is Novitero's operational status?

Novitero is currently non-active, having ceased operations in January 2021.

What is Novitero's total funding?

Novitero has raised a total of $50,000 across one Pre-Funding round.